drugset / Trial / NCT02723071
A Study of Ocrelizumab in Participants With Follicular Non-Hodgkin's Lymphoma (NHL)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, pharmacokinetics, and anti-tumor efficacy of ocrelizumab in participants with progressive follicular NHL.
Timeline
- Start
- 2005-05
- Primary completion
- 2008-01
- Completion
- 2008-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ocrelizumab | Monoclonal antibody | 200 mg/m2 | Intravenous |
| Subject | Ocrelizumab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Subject | Ocrelizumab | Monoclonal antibody | 750 mg/m2 | Intravenous |